In vitro susceptibilities of zygomycetes to conventional and new antifungals.
about
Novel perspectives on mucormycosis: pathophysiology, presentation, and management.Disseminated infection with Prototheca zopfii after unrelated stem cell transplantation for leukemiaDirect analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometryInvasive Apophysomyces variabilis infection in a burn patientRecent advances in the management of mucormycosis: from bench to bedsideMolecular and phenotypic evaluation of Lichtheimia corymbifera (formerly Absidia corymbifera) complex isolates associated with human mucormycosis: rehabilitation of L. ramosaMucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia speciesActivities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.Molecular detection and identification of zygomycetes species from paraffin-embedded tissues in a murine model of disseminated zygomycosis: a collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection SAntifungal susceptibility profile of human-pathogenic species of LichtheimiaIn vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds.Recent advances in the treatment of mucormycosis.Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole.Posaconazole as salvage therapy for zygomycosis.Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infectionMolecular identification of zygomycetes from culture and experimentally infected tissues.Rapid susceptibility testing of medically important zygomycetes by XTT assay.Genetic identification of the main opportunistic Mucorales by PCR-restriction fragment length polymorphism.Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility patternComparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers.The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.Linezolid for the treatment of drug-resistant infections.Update on the safety of linezolid.Epidemiology and treatment approaches in management of invasive fungal infectionsVoriconazole in the management of nosocomial invasive fungal infections.Human Fungal Pathogens of Mucorales and Entomophthorales.Etest cannot be recommended for in vitro susceptibility testing of mucorales.Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.Future directions in mucormycosis research.Carbon assimilation profiles as a tool for identification of zygomycetesRare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus.Liposomal amphotericin B: clinical experience and perspectives.Voriconazole: review of a broad spectrum triazole antifungal agent.Posaconazole: clinical pharmacology and potential for management of fungal infections.Activity of posaconazole in the treatment of central nervous system fungal infections.Fungal CNS infections in patients with hematologic malignancy.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.
P2860
Q24530554-4FFBF598-C73D-44AC-BE85-49ABDD33FC33Q24563379-667D9F16-8084-4AA3-875C-497A46A77541Q24604418-C41051CE-5282-4D3C-A31E-0A478950328EQ24616334-96619609-5934-4E43-9C88-EB8E74A6872DQ24642450-59C0D05F-5D1B-4885-931F-23019537A585Q24647446-EE159AB1-5B04-4C59-B795-1AE72C0AD423Q28389719-E18473EB-03C4-4FCB-BFA7-BD5415EAEF7AQ33188045-89E781C6-23DD-435A-8A8C-62A195FA6738Q33805542-5A1FF226-996C-41ED-BF25-793EDA4091BCQ33909379-A9058659-1672-4532-9554-7A7A14BE350CQ33962824-8B28E945-9122-4703-86C8-8FF31325B20CQ34045255-6B8FFE18-2BAA-4B99-850F-8687EF9F3992Q34161213-41C5B8C0-BE3F-4A4E-A2A8-D9572B889CF7Q34301592-954EB0E1-F96B-4E7F-8A5D-C7860136FA2AQ34301611-EBEB5405-DCAA-4EC1-A12E-34D817076DD0Q34352014-365CEB9F-4911-496C-8C38-ED12032ADF41Q34430706-D7BE1C7C-524A-416A-824B-82B2C3EDC9FDQ34430832-B72C6F6E-D3D1-457A-9A80-2EFA20984FF6Q34431828-FFA35CAE-35EF-42B7-8A69-5557F37CDDE3Q34433129-A1A6C284-7D96-498C-9F6C-BEFE501A5B5AQ34596761-250B11C5-9D04-431A-ADC5-06E74205F7B9Q34648517-A107AEE5-74B4-46DA-BD15-1F941CB37934Q34672655-37709717-C8B9-49CA-AABD-FE0898158269Q34680661-8C2B3FE9-0353-4F8A-A364-415C7EC8E839Q34894133-E76CD1E9-E1B9-4662-82B1-3D7DAB0A9276Q34987632-B7F11633-219A-4CAE-95DC-FB527C6CB0A8Q35089772-9A9A0153-AE2B-42DD-A8CD-9C6E133F1BC5Q35166823-0AC782B4-792A-4FA6-8AC5-90EAAA0E83C8Q35245238-2D0CFA1B-B22A-40CC-BDC7-BC989FFCEF06Q35595623-E3DAA5F5-8A87-428B-A40D-AE4B9061AFC1Q35668229-8CC1AC7E-D699-4335-A50C-79999411A784Q35672102-464BF51A-EC4D-4B3E-B8F8-09849F0E39A1Q35784447-06FE2943-EDE9-44C7-8208-4F7AD46B7612Q35912243-A48BB34B-4B71-49A0-BE88-905C89FA4A2EQ36140647-ED877AB1-5AF4-4FC2-BEC1-529D5AC463E1Q36164008-7FB1C07C-E9D7-4383-AB3A-6303773FBF98Q36233491-69C1CAA6-EEA7-44A2-9737-51FBE4B78019Q36246196-0DE4D270-F9FF-4322-9D59-8B831DA270C8Q36278069-3B6BE191-5E38-4EB3-9306-1417657803DAQ36491819-154CACC7-8629-4A86-95D2-18B4FCAEA71E
P2860
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
@en
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
@nl
type
label
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
@en
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
@nl
prefLabel
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
@en
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
@nl
P2093
P356
P1476
In vitro susceptibilities of zygomycetes to conventional and new antifungals.
@en
P2093
Eurofung Network
Jacques F G M Meis
Joseph Meletiadis
Paul E Verweij
P356
10.1093/JAC/DKG020
P407
P577
2003-01-01T00:00:00Z